Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
There’s a new diet and prostate cancer story “doing the rounds” in the media. It started out stating that dietary changes can induce “substantial” effects on PSA doubling times among men who have received first-line treatment for prostate cancer. The problem with the story is that is based on a small pilot study published last [...]
Filed under: Living with Prostate Cancer, Management | Tagged: diet, journalist, media, misrepresentation, progression, risk, vegetarian | 2 Comments »
Today’s news reports are focused on issued around epidemiology, prevention, diagnosis, treatment decisions, and the role of humor in prostate cancer support group interactions.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: active surveillance, arsenic, DRE, finasteride, humor, masculinity, Prevention, support groups | Leave a Comment »
According to another Reuters report, men who develop prostate cancer and who carry one of three possible hereditary mutations to the so-called breast cancer genes BRCA1 and BRCA2 appear to be at particularly high risk for an aggressive form of the disease.
Filed under: Diagnosis, Management, Risk | Tagged: aggressive disease, BRCA1, BRCA2, mutation, risk | Leave a Comment »
There are six news reports today, most of which can be dealt with quickly and briefly. They run the gamut from antibiotic prophylaxis prior to prostate biopsy to the effects of androgen deprivation therapy on cognition.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: androgen deprivation, antibiotic, arsenic, biopsy, cognition, photodynamic therapy, prophylaxis, serum DNA assays, zinc concentration imaging | Leave a Comment »
As reported by Reuters Health earlier today, the majority of men with early-stage, low- or moderate-grade prostate cancer do not, in fact die from this disease. This topic has been carefully addressed by a recent article in the January issue of the Journal of the American Geriatric Society. Prevention and management of other health conditions [...]
Filed under: Living with Prostate Cancer, Management | Tagged: cardiovascular risk, diabetes, mortality, obesity, survival | Leave a Comment »
Reports summarized today include one on the potential of “dynamic contrast-enhanced” magnetic resonance imaging (DCE-MRI) and a second on the impact of obesity on risk for prostate cancer detection.
Filed under: Diagnosis, Management, Risk | Tagged: dynamic contrast-enhanced, MRI, obesity, risk | Leave a Comment »
Yet another article by Dana Jennings appeared in today’s New York Times. In his latest “Epistle to the Gleasonized,” Mr. Jennings offers a list of post-op “home truths” from his personal experience for those who will continue to come after!
Filed under: Living with Prostate Cancer | Tagged: Dana Jennings | Leave a Comment »
D’Amico and colleagues have conducted a retrospective analysis of data from > 300 patients in an attempt to compare biochemical (PSA-based) outcomes of men with high-risk prostate cancer based on the presence or absence of any amount of Gleason pattern 5 cancer in their initial biopsy findings (as a primary, secondary, or tertiary pattern). The [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Gleason pattern, risk, stratification, tertiary | 5 Comments »
A “Beyond the Abstract” article on UroToday has again raised the issue of the appropriateness of finasteride as a suitable agent for the prevention of prostate cancer in appropriately selected men known to be at significant risk for this disease.
Filed under: Prevention, Risk | Tagged: finasteride, Prevention | Leave a Comment »
Today’s news deals with such items as: Toxicities associated with hypofractionated, intensity-modulated radiation therapy Incidental prostate cancer in male patients undergoing radical cystoprostatectomy for treatment of bladder cancer A Spanish review of photodynamic therapy A proposed mechanism of action for the investigational drug Apoptone™ (HE3235)
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment, Uncategorized | Tagged: Apoptone, cystoprostatectomy, HE3235, hypofractionated, IMRT, photodynamic therapy | Leave a Comment »
We had previously posted a brief comment on a paper by Mearini et al., who had reported on Italian experience of the use of high-intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer.
Filed under: Management, Treatment | Tagged: HIFU | Leave a Comment »
There has been almost no new prostate cancer news over the past few days, which accounts for the general lack of new posts to this page and (probably) for the overblown reporting of the potential utility of a modified form of measles virus in treatment of prostate cancer.
Filed under: Drugs in development | Tagged: immunotherapy, MV-CEA virus | 2 Comments »
Once upon a time there was a prostate cancer awareness week in the third week of September every year. Then (at least in America) it grew into prostate cancer awareness month. Now the BrownBryd Prostate Cancer Foundation (based in New York) has started to promote prostate cancer awareness day on February 2 …
Filed under: Diagnosis, Risk | Tagged: BrownByrd Prostate cancer Awareness Day | 3 Comments »
Biochemical recurrence after first-line treatment for localized prostate cancer affects some 30 to 40 percent of prostate cancer patients. Two articles to be published in the March 2009 issue of The Journal of Urology provide interesting new data on the treatment of men who have either failed first-line surgical treatment or are at high risk for such failure.
Filed under: Drugs in development, Management, Treatment | Tagged: adjuvant radiotherapy, ADT, androgen deprivation, progression, survival, thalidomide | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site